Endometriosis Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Endometriosis Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Endometriosis Treatment Market is expected to register a CAGR of 5.3% over the forecast period, 2022-2027.

COVID-19 pandemic had a substantial impact on patients with chronic disease conditions like endometriosis. The strict lockdowns and government regulations intended to slow down the spread of COVID-19 resulted in a decrease in demand for products across all segments. In wake of the COVID-19 outbreak, women with endometriosis are particularly exposed to the risk of post-traumatic stress disorder during the SARS-CoV-2 pandemic, especially if they are older or have higher levels of anxiety.

As per the articles published in October 2021 titled ‘Effects of the SARS-CoV-2 pandemic on women affected by endometriosis in the National Library of Medicine, 68.8% were quite extremely worried about not being able to access gynecologic care during this period, thus, the COVID-19 had a significant impact on the endometriosis treatment market.

According to World Health Organization, in 2021 endometriosis affects roughly 10% (190 million) of reproductive-age women and girls globally. Further, the rise in the prevalence of endometriosis, growing awareness of the disease, and growing need for early diagnosis are among the major factors driving the growth of the studied market. Such factors are likely to boost the adoption of the endometriosis treatment market, thereby contributing to the studied market growth.

In addition, growing awareness and research and development funding by major players in the market are positively affecting the growth of the studied market. For instance, in February 2021 the DBT Wellcome India Alliance is supporting a major national research project ‘Endometriosis Clinical and Genetic Research in India (ECGRI)’ that aims to broaden understanding of the clinical phenotypes and genetic risks associated with endometriosis. Additionally, in February 2021, the European Union is supporting a major international research and innovation project that aims to improve the treatment and quality of life of those with endometriosis.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period. However, the high cost of endometriosis treatment is likely to impede the market growth.

Key Market TrendsPain Medication segment is Expected to Witness Significant Growth Over the Forecast Period

Endometriosis is associated with painful symptoms such as chronic pelvic pain, dysmenorrhea and dyspareunia, infertility, and psychological suffering among others. The medical treatment of endometriosis can deal with painful symptoms of the disease and, consequently, reduce the negative impact on quality of life and mental health. The medication has a high safety profile, good tolerance, few side effects, and reasonable costs. Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most common pain medications for endometriosis. Over-the-counter NSAIDs include aspirin, ibuprofen, and naproxen. NSAIDs block the development of prostaglandins, a type of biological compound produced in the body. Prostaglandins cause swelling, pain, and inflammation that many women with endometriosis experience during their periods.

Furthermore, a continuous collaboration by major players in the market is positively affecting the growth of the segment. For instance, in February 2022 ObsEva SA announced a strategic licensing agreement with Theramex to support the commercialization and market introduction of linzagolix across global markets outside of the United States, Canada, and Asia. Linzagolix is in development as a potential treatment for endometriosis-associated pain, and ObsEva recently announced positive topline results for its first Phase 3 trial (EDELWEISS 3) in this indication.

North America is Expected to Dominate the Endometriosis Treatment Market

North America is expected to dominate the market owing to factors such as the easy availability of technologically advanced products, the rising prevalence of endometriosis, and awareness about health in this region. For instance, according to the data published by the Office on Women's Health in 2021, endometriosis affects more than 11% of women between ages 15 and 44 and is common among women in their 30s and 40s in the United States.

Key product launches, high concentration of market players, or manufacturer's presence in the United States are some of the factors driving the growth of the endometriosis Treatment Market in the country. For instance, in August 2022, Myovant Sciences and Pfizer announce United States Food and Drug Administration (FDA) approved MYFEMBREE for the management of moderate to severe pain associated with endometriosis in pre-menopausal women. The drug offers a once-daily effective treatment option for the management of moderate to severe endometriosis pain, with a treatment duration of up to 24 months. Therefore, owing to the above-mentioned factors North America Endometriosis Treatment Market is expected to dominate and register higher growth over the forecast period.

Competitive Landscape

The Endometriosis Treatment Market is fragmented in nature due to the presence of several companies operating globally as well as regionally. Most of the big companies are focusing on research and development to bring innovative products to the market. Some of the major players include Bayer AG, Lannett, Pfizer Inc., Sun Pharmaceutical Industries Limited, Cipla Limited, Teva Pharmaceutical Industries Ltd, Zydus Healthcare Limited, TerSera Therapeutics USA, Tolmar Pharmaceuticals, Inc., AbbVie Inc., and Sandoz AG.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.